MRD rates in PB and BM. (A) MRD rates in PB according to time after last dose of obinutuzumab in the R/R population. (B) MRD rates in BM by best response achieved in the R/R population. (C) MRD rates in PB according to time after the last dose of obinutuzumab in the 1L population. (D) MRD rates in PB after completion of all treatment (last dose of venetoclax) in the 1L population. (E) MRD rates in BM by best response achieved in the 1L population. “Discontinued” specifies the number of patients who discontinued the study before the landmark time point due to PD, death, or AE (if applicable). “Missing” specifies the number of patients who reached the landmark time point but did not have samples available for MRD assessment. *Of 43 R/R patients included in the efficacy analysis, 1 was excluded from the MRD analysis because of an undetectable MRD result at screening assumed to be due to the use of anti-CD20 <2 months before starting the trial. †Two patients discontinued the study before achieving this time point due to other reasons than PD, death, or AE, and were excluded from the MRD analysis at this landmark time point. ‡Undetermined: <10⁻⁴, but <200 000 leukocytes analyzed. §Median 4.4 months (range, 2.8-8.5 months) from last dose of venetoclax. CRi, complete response with incomplete marrow recovery; G, GA101/obinutuzumab; Tx, treatment.